TEVA PHARMACEUTICAL INDUSTRIES LTD
For the period ended Dec 31, 2023. Filed Feb 12, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 12, 2024
TEVA$42.97+0.8%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Balance sheets
| December 31, 2023 | December 31, 2022 | |
|---|---|---|
| ASSETS | ||
| Current assets: | ||
| Cash and cash equivalents | $3,226 | $2,801 |
| Accounts receivables, net of allowance for credit losses of $95 million and $91 million as of December 31, 2023 and December 31, 2022, respectively | 3,408 | 3,696 |
| Inventories | 4,021 | 3,833 |
| Prepaid expenses | 1,255 | 1,162 |
| Other current assets | 504 | 549 |
| Assets held for sale | 70 | 10 |
| Total current assets | 12,485 | 12,051 |
| Deferred income taxes | 1,812 | 1,458 |
| Other non-current assets | 470 | 441 |
| Property, plant and equipment, net | 5,750 | 5,739 |
| Operating lease right-of-use assets | 397 | 419 |
| Identifiable intangible assets, net | 5,387 | 6,270 |
| Goodwill | 17,177 | 17,633 |
| Total assets | $43,479 | $44,011 |
| LIABILITIES AND EQUITY | ||
| Current liabilities: | ||
| Short-term debt | $1,672 | $2,109 |
| Sales reserves and allowances | 3,535 | 3,750 |
| Accounts payables | 2,602 | 1,887 |
| Employee-related obligations | 611 | 566 |
| Accrued expenses | 2,771 | 2,151 |
| Other current liabilities | 1,056 | 1,005 |
| Total current liabilities | 12,247 | 11,469 |
| Long-term liabilities: | ||
| Deferred income taxes | 606 | 548 |
| Other taxes and long-term liabilities | 4,019 | 3,945 |
| Senior notes and loans | 18,161 | 19,103 |
| Operating lease liabilities | 320 | 349 |
| Total long-term liabilities | 23,106 | 23,944 |
| Total liabilities | 35,353 | 35,413 |
| Equity: | ||
| Teva shareholders’ equity: | ||
| Ordinary shares of NIS 0.10 par value per share; December 31, 2023 and December 31, 2022: authorized 2,495 million shares; issued 1,227 million shares and 1,217 million shares, respectively | 57 | 57 |
| Additional paid-in capital | 27,807 | 27,688 |
| Accumulated deficit | (13,534) | (12,975) |
| Accumulated other comprehensive loss | (2,697) | (2,838) |
| Treasury shares as of December 31, 2023 and December 31, 2022: 106 million ordinary shares | (4,128) | (4,128) |
| 7,506 | 7,804 | |
| Non-controlling interests | 620 | 794 |
| Total equity | 8,126 | 8,598 |
| Total liabilities and equity | $43,479 | $44,011 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.